Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
Key facts
- Who runs it
- Health Clinics Limited
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 3
- Started
- 23 May 2022
- Expected to end
- 23 Sept 2027
- Type of study
- Interventional
- Treatments tested
- Metabolic treatment
- Record updated
- 18 July 2022
- Why it stopped
- Prospective recruitment not possible
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Male or female 18-85 years old
- Diagnosed with cancer and have had such diagnosis confirmed by scan, blood markers and/or biopsy
- Is receiving or will shortly receive standard of care therapy or has completed standard of care treatment; and
- Signed and dated written informed consent from the participant or LAR
Who cannot take part
- Major organ failure, renal, lung and liver failure
- History of cardiac or respiratory failure
- History of recent myocardial infarction
- Hypersensitivity to any of the treatment drugs or excipients
- Mentally incapacitated and no guardian able to sign on patients Clinical study protocol, version 5.0 METRICS TRIAL, Metabolic Cancer 001 5th Apr 2016 Confidential Page 5 of 65 behalf
- Participants having active liver disease or unexplained persistent elevation of serum transaminases > 3 times the upper limit of normal
- Participants with a creatinine clearance < 60mL/min
- Pregnant or lactating females or females who are planning a pregnancy during the course of the study
- Participants with diabetic ketoacidosis or diabetic pre-coma
- Ileum, colon or stomach part or full removal rendering them unable to take the study medicines
- Unable to eat or keep food or medicines down or is being fed intravenously
- Is too frail and weak to withstand the study medicines in the opinion of the study doctor
- Is Unlikely to survive more than 1 month under standard of care, in the opinion of the study doctor
- If the patient is on any medicines contraindicated with the study medicines (see Appendix 3)
- History or presence of alcohol or substance abuse
- Participation in a clinical trial of an investigational medicinal product that is viewed by the Study Physician to be a significant risk to the participant's safety
- Direct employee of the study site
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to determine the effectiveness of a regimen of selected metabolic treatments for patients with cancer in a real world setting and to conduct exploratory analysis on the relationship between the degree of response and changes in biochemical markers (such as glucose and lipid levels).
The group in the trial
- Metabolic TreatmentTreatment being tested
Subjects will take the following treatments and have their data collected from their medical records every 3 months. * Oral atorvastatin up to 80mg uid, for study duration. * Oral metformin up to 1000mg uid, increased to bid if tolerated after 2 weeks, for study duration. * Oral doxycycline 100mg uid, for study duration. * Oral Mebendazole 100mg uid, for study duration.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Non Randomised, Non Blinded Real World Trial of the Safety, Tolerability and Effectiveness of Metabolic Medicines for the Treatment of Cancer Compared Against Matched Controls
- Record updated
- 18 July 2022